286 related articles for article (PubMed ID: 32423157)
1. Genetic Alterations Featuring Biological Models to Tailor Clinical Management of Pancreatic Cancer Patients.
Nelson SR; Walsh N
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32423157
[TBL] [Abstract][Full Text] [Related]
2. Generation and application of patient-derived xenograft models in pancreatic cancer research.
Wang CF; Shi XJ
Chin Med J (Engl); 2019 Nov; 132(22):2729-2736. PubMed ID: 31725451
[TBL] [Abstract][Full Text] [Related]
3. Modelling of pancreatic cancer biology: transcriptomic signature for 3D PDX-derived organoids and primary cell line organoid development.
Nelson SR; Zhang C; Roche S; O'Neill F; Swan N; Luo Y; Larkin A; Crown J; Walsh N
Sci Rep; 2020 Feb; 10(1):2778. PubMed ID: 32066753
[TBL] [Abstract][Full Text] [Related]
4. In vivo models of pancreatic ductal adenocarcinoma.
Vudatha V; Herremans KM; Freudenberger DC; Liu C; Trevino JG
Adv Cancer Res; 2023; 159():75-112. PubMed ID: 37268402
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility.
Knudsen ES; Balaji U; Mannakee B; Vail P; Eslinger C; Moxom C; Mansour J; Witkiewicz AK
Gut; 2018 Mar; 67(3):508-520. PubMed ID: 28073890
[TBL] [Abstract][Full Text] [Related]
6. Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devastating cancer?
Sereti E; Karagianellou T; Kotsoni I; Magouliotis D; Kamposioras K; Ulukaya E; Sakellaridis N; Zacharoulis D; Dimas K
J Proteomics; 2018 Sep; 188():107-118. PubMed ID: 29398619
[TBL] [Abstract][Full Text] [Related]
7. Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective.
Perales-Patón J; Piñeiro-Yañez E; Tejero H; López-Casas PP; Hidalgo M; Gómez-López G; Al-Shahrour F
Public Health Genomics; 2017; 20(2):81-91. PubMed ID: 28858862
[TBL] [Abstract][Full Text] [Related]
8. A Comparative Quantitative LC-MS/MS Profiling Analysis of Human Pancreatic Adenocarcinoma, Adjacent-Normal Tissue, and Patient-Derived Tumour Xenografts.
Coleman O; Henry M; O'Neill F; Roche S; Swan N; Boyle L; Murphy J; Meiller J; Conlon NT; Geoghegan J; Conlon KC; Lynch V; Straubinger NL; Straubinger RM; McVey G; Moriarty M; Meleady P; Clynes M
Proteomes; 2018 Nov; 6(4):. PubMed ID: 30404163
[TBL] [Abstract][Full Text] [Related]
9. Patient Derived Xenografts Expand Human Primary Pancreatic Tumor Tissue Availability for
Brock RM; Beitel-White N; Coutermarsh-Ott S; Grider DJ; Lorenzo MF; Ringel-Scaia VM; Manuchehrabadi N; Martin RCG; Davalos RV; Allen IC
Front Oncol; 2020; 10():843. PubMed ID: 32528898
[TBL] [Abstract][Full Text] [Related]
10. Microfluidic Platforms for High-Throughput Pancreatic Ductal Adenocarcinoma Organoid Culture and Drug Screening.
Geyer M; Queiroz K
Front Cell Dev Biol; 2021; 9():761807. PubMed ID: 35004672
[TBL] [Abstract][Full Text] [Related]
11. Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models.
Garcia PL; Miller AL; Yoon KJ
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32456018
[TBL] [Abstract][Full Text] [Related]
12. Modeling human pancreatic ductal adenocarcinoma for translational research: current options, challenges, and prospective directions.
Suri R; Zimmerman JW; Burkhart RA
Ann Pancreat Cancer; 2020 Dec; 3():. PubMed ID: 33889840
[TBL] [Abstract][Full Text] [Related]
13. Organoid models for translational pancreatic cancer research.
Tiriac H; Plenker D; Baker LA; Tuveson DA
Curr Opin Genet Dev; 2019 Feb; 54():7-11. PubMed ID: 30844513
[TBL] [Abstract][Full Text] [Related]
14. Modeling Obesity-Driven Pancreatic Carcinogenesis-A Review of Current In Vivo and In Vitro Models of Obesity and Pancreatic Carcinogenesis.
Kfoury S; Michl P; Roth L
Cells; 2022 Oct; 11(19):. PubMed ID: 36231132
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
[TBL] [Abstract][Full Text] [Related]
16. Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids.
Palzer J; Mues B; Goerg R; Aberle M; Rensen SS; Olde Damink SWM; Vaes RDW; Cramer T; Schmitz-Rode T; Neumann UP; Slabu I; Roeth AA
Int J Nanomedicine; 2021; 16():2965-2981. PubMed ID: 33935496
[TBL] [Abstract][Full Text] [Related]
17. Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models.
Hoare O; Fraunhoffer N; Elkaoutari A; Gayet O; Bigonnet M; Roques J; Nicolle R; McGuckin C; Forraz N; Sohier E; Tonon L; Wajda P; Boyault S; Attignon V; Tabone-Eglinger S; Barbier S; Mignard C; Duchamp O; Iovanna J; Dusetti NJ
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34069519
[No Abstract] [Full Text] [Related]
18. Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinoma.
Rittmann MC; Hussung S; Braun LM; Klar RFU; Biesel EA; Fichtner-Feigl S; Fritsch R; Wittel UA; Ruess DA
Sci Rep; 2021 Apr; 11(1):7499. PubMed ID: 33820913
[TBL] [Abstract][Full Text] [Related]
19. Challenges in genomic analysis of model systems and primary tumors of pancreatic ductal adenocarcinoma.
Hyun S; Park D
Comput Struct Biotechnol J; 2022; 20():4806-4815. PubMed ID: 36147673
[TBL] [Abstract][Full Text] [Related]
20. Establishment of Patient-derived Orthotopic Xenografts (PDX) as Models for Pancreatic Ductal Adenocarcinoma.
Magouliotis DE; Lafazanis K; Koutsougianni F; Sakellaridis N; Ioannou M; Zacharoulis D; Dimas K
In Vivo; 2022; 36(3):1114-1119. PubMed ID: 35478141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
